11454 related articles for article (PubMed ID: 12231175)
1. Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma.
Zhang L; Akbulut H; Tang Y; Peng X; Pizzorno G; Sapi E; Manegold S; Deisseroth A
Mol Ther; 2002 Sep; 6(3):386-93. PubMed ID: 12231175
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
3. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma.
Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
Hum Gene Ther; 2004 Jul; 15(7):637-47. PubMed ID: 15242524
[TBL] [Abstract][Full Text] [Related]
4. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Peng XY; Won JH; Rutherford T; Fujii T; Zelterman D; Pizzorno G; Sapi E; Leavitt J; Kacinski B; Crystal R; Schwartz P; Deisseroth A
Cancer Res; 2001 Jun; 61(11):4405-13. PubMed ID: 11389068
[TBL] [Abstract][Full Text] [Related]
5. Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy.
Liu Y; Ye T; Maynard J; Akbulut H; Deisseroth A
Cancer Gene Ther; 2006 Apr; 13(4):346-56. PubMed ID: 16179927
[TBL] [Abstract][Full Text] [Related]
6. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
[TBL] [Abstract][Full Text] [Related]
7. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.
Kurihara T; Brough DE; Kovesdi I; Kufe DW
J Clin Invest; 2000 Sep; 106(6):763-71. PubMed ID: 10995787
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by alpha-lactalbumin promoter.
Li X; Zhang J; Gao H; Vieth E; Bae KH; Zhang YP; Lee SJ; Raikwar S; Gardner TA; Hutchins GD; VanderPutten D; Kao C; Jeng MH
Mol Cancer Ther; 2005 Dec; 4(12):1850-9. PubMed ID: 16373700
[TBL] [Abstract][Full Text] [Related]
9. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors.
Hernandez-Alcoceba R; Pihalja M; Wicha MS; Clarke MF
Hum Gene Ther; 2000 Sep; 11(14):2009-24. PubMed ID: 11020800
[TBL] [Abstract][Full Text] [Related]
10. Construction of a novel oncolytic adenoviral vector and its biological characteristics.
Zhang M; Zhang X; Han Z; Chen X; Yang L; Sheng Y; Wen J
Oncol Rep; 2013 Feb; 29(2):798-804. PubMed ID: 23165979
[TBL] [Abstract][Full Text] [Related]
11. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice.
Sarkar D; Su ZZ; Vozhilla N; Park ES; Gupta P; Fisher PB
Proc Natl Acad Sci U S A; 2005 Sep; 102(39):14034-9. PubMed ID: 16172403
[TBL] [Abstract][Full Text] [Related]
12. Development of a melanoma-specific adenovirus.
McCart JA; Wang ZH; Xu H; Hu Y; Park B; Alexander HR; Bartlett DL
Mol Ther; 2002 Oct; 6(4):471-80. PubMed ID: 12377188
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy.
Liu Y; Deisseroth A
Cancer Gene Ther; 2006 Sep; 13(9):845-55. PubMed ID: 16710344
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus.
Lim HY; Ahn M; Chung HC; Gardner TA; Kao C; Lee SJ; Kim SJ
Cancer Gene Ther; 2004 Aug; 11(8):532-8. PubMed ID: 15167900
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
16. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.
Nettelbeck DM; Rivera AA; Balagué C; Alemany R; Curiel DT
Cancer Res; 2002 Aug; 62(16):4663-70. PubMed ID: 12183423
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific therapeutic effect induced by an oncolytic adenoviral vector containing heat shock protein 70 and prodrug activation genes.
Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
Gene Ther; 2006 Aug; 13(16):1235-43. PubMed ID: 16617300
[TBL] [Abstract][Full Text] [Related]
18. Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication-competent CD95L adenovirus.
Fecker LF; Schmude M; Jost S; Hossini AM; Picó AH; Wang X; Schwarz C; Fechner H; Eberle J
Exp Dermatol; 2010 Aug; 19(8):e56-66. PubMed ID: 19725869
[TBL] [Abstract][Full Text] [Related]
19. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
20. Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand.
Fecker LF; Rückert S; Kurbanov BM; Schmude M; Stockfleth E; Fechner H; Eberle J
Hum Gene Ther; 2011 Apr; 22(4):405-17. PubMed ID: 20977303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
